美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Russell Investments Core Plus Bond ETF

24.74

-0.0256-0.10%

盤後：24.760.0256+0.10%16:04 EDT

成交量：39

成交額：965

市值：5,985.88萬

市盈率：- -

高：24.74

開：24.76

低：24.74

收：24.76

52周最高：25.19

52周最低：24.72

股本：242.00萬

流通股本：242.00萬

量比：0.80

換手率：0.00%

股息：0.12

股息率：0.49%

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

港股異動 | 先聲藥業(02096)早盤升逾5% 今日將發中期業績創新藥及BD收入帶動業績高增

【券商聚焦】國盛證券首予石藥集團（01093）買入評級指其創新轉型與BD出海雙輪驅動

海外BD大單落定，國產胰島素龍頭借力減重藥能否開啓新增長曲線？

全球客户「反向出差」到中國

別慌！機構資金都流向了這裏！

证券市场周刊

三筆重磅BD同日落地，創新藥出海景氣走高！T+0恒生創新藥ETF華泰柏瑞（520500）近一年累計「吸金」超25億元

白宮新聞秘書辭職；交易所BD曬12萬U提成引熱議；但斌調倉曝光；A股股民轉戰X

從「搶BD」到重現金流創新藥產業投資邏輯生變

從「搶BD」到重現金流創新藥產業投資邏輯生變

百濟神州與Revolution Medicines宣佈合作；甘李藥業宣佈減肥新藥海外BD | 醫藥早參

每日经济新闻

從BD高光到虧損迴歸，百利天恒面臨什麼考題？

BD交易破千億美元中國創新藥距離「全球大單品」還有多遠？

华夏时报网

BD 2026財年第三季度財報：營收增長但營業利潤下滑

TradingKey中文

「新新三樣」之中國創新藥：千億級BD背後的體系突圍

华夏时报网

【券商聚焦】華泰證券維持先聲藥業（02096）買入評級指新品放量及BD常態化

第十二批國採現場：多家金融機構到場介紹「集採貸」「BD貸」等服務產品

上半年BD交易破千億，創新藥長期趨勢向好？

專訪百奧賽圖沈月雷：「揭秘」一筆四個月就達成的BD合作

遼BD***、遼BF*、遼BT、遼B***，你被曝光了！大連為啥這麼做？

超百億資金悄悄買入這個賽道！

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/stock/BD/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BD\",,,,,undefined,":{"symbol":"BD","market":"US","secType":"STK","nameCN":"Russell Investments Core Plus Bond ETF","latestPrice":24.735,"timestamp":1787342400000,"preClose":24.7606,"halted":0,"volume":39,"hourTrading":{"tag":"盘后","latestPrice":24.7606,"preClose":24.735,"latestTime":"16:04 EDT","volume":2,"amount":49.47,"timestamp":1787342650304,"change":0.0256,"changeRate":0.001035,"amplitude":0},"delay":0,"changeRate":-0.0010339006324564322,"floatShares":2420004,"shares":2420004,"eps":0,"marketStatus":"休市中","change":-0.0256,"latestTime":"08-21 16:00:00 EDT","open":24.7606,"high":24.735,"low":24.735,"amount":965,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1787558400000},"marketStatusCode":7,"adr":0,"exchange":"ARCA","adjPreClose":24.7606,"nav":24.69152,"aum":59753478.67,"dividendRate":0.004881,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":24.7606,"preClose":24.735,"latestTime":"16:04 EDT","volume":2,"amount":49.47,"timestamp":1787342650304,"change":0.0256,"changeRate":0.001035,"amplitude":0},"volumeRatio":0.7991816380026854},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BD\",,,,,undefined,":{"symbol":"BD","floatShares":2420004,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.7991816380026854,"shares":2420004,"dividePrice":0.120736,"high":24.735,"amplitude":0,"preClose":24.7606,"low":24.735,"week52Low":24.72,"pbRate":"--","week52High":25.19,"institutionHeld":0,"latestPrice":24.735,"eps":0,"divideRate":0.004881,"volume":39,"delay":0,"ttmEps":0,"open":24.7606,"prevYearClose":25.08,"prevWeekClose":24.775,"prevMonthClose":24.7678,"prevQuarterClose":25.19,"fiveDayClose":24.775,"twentyDayClose":24.795},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BD\",params:#limit:5,,,undefined,":[{"date":"2026-08-04","symbol":"BD","amount":0.120736,"announcedDate":"2026-08-03","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-08-04","defaultRemindTime":1785850200000,"name":"Russell Investments Core Plus Bond ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-08-06","payableDate":"2026-08-04","currency":"USD","dateTimestamp":1785816000000,"payDate":"2026-08-06"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BD\",market:\"US\",,,undefined,":[{"executeDate":"2026-08-04","recordDate":"2026-08-04","paymentDate":"2026-08-06","value":0.120736,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BD\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BD\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2660477171","title":"港股異動 | 先聲藥業(02096)早盤升逾5% 今日將發中期業績 創新藥及BD收入帶動業績高增","url":"https://stock-news.laohu8.com/highlight/detail?id=2660477171","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660477171?lang=zh_tw&edition=fundamental","pubTime":"2026-08-20 10:32","pubTimestamp":1787193141,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，先声药业早盘涨超5%，截至发稿，涨4.27%，报12.69港元，成交额4017.4万港元。消息面上，先声药业将于8月21日召开2026年中期业绩发布会。主要归因于创新药收入和对外授权许可收入的增加。预计公司全年内生业务维持中报预告趋势，同时利润端受益BD继续跨越式提升。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1482411.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","02096","BK1161","BK1574","BK4585","KCAI","BD","IBBQ","MEDX","06978","159992","BK4588","LNGR","BK1191","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660448051","title":"【券商聚焦】國盛證券首予石藥集團（01093）買入評級 指其創新轉型與BD出海雙輪驅動","url":"https://stock-news.laohu8.com/highlight/detail?id=2660448051","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660448051?lang=zh_tw&edition=fundamental","pubTime":"2026-08-19 15:44","pubTimestamp":1787125471,"startTime":"0","endTime":"0","summary":"国盛证券指出，公司构建“自研管线+BD出海”双轮驱动创新研发体系。通过可比公司估值法，给予公司2027年23倍PE，对应目标价13.41港元，首次覆盖给予“买入”评级。报告同时提示研发失败、产品商业化不及预期、BD里程碑收入确认节奏不确定、集采政策持续影响、估值与盈利预测假设及专利知识产权等风险。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250110/YzMzOTE1NTA2MzA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/YzMzOTE1NTA2MzA=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1988694","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KCE","01093","002670","BD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659421174","title":"海外BD大單落定，國產胰島素龍頭借力減重藥能否開啓新增長曲線？","url":"https://stock-news.laohu8.com/highlight/detail?id=2659421174","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659421174?lang=zh_tw&edition=fundamental","pubTime":"2026-08-16 17:05","pubTimestamp":1786871100,"startTime":"0","endTime":"0","summary":"海归博士创立的胰岛素龙头，净利润难复巅峰在凭借博凡格鲁肽获得市场高度关注之前，甘李药业最为人熟知的身份是国产胰岛素龙头。在国内三代胰岛素市场上，除诺和诺德、赛诺菲、礼来三大外企外，甘李药业市场份额最高，是国产三代胰岛素龙头。拿下海外授权许可大单，甘李药业能否迎来爆发？此次与美纳里尼的授权金额，也创出了博凡格鲁肽授权金额新高。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hyyj/2026-08-16/doc-ininnzcn1015795.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659317314","title":"全球客户「反向出差」到中國","url":"https://stock-news.laohu8.com/highlight/detail?id=2659317314","media":"央视财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659317314?lang=zh_tw&edition=fundamental","pubTime":"2026-08-15 22:18","pubTimestamp":1786803480,"startTime":"0","endTime":"0","summary":"在央视财经《对话》节目中，主持人陈伟鸿与几位中国科技企业的创始人聊起了一个有趣的变化：过去，中国企业出海往往意味着带着样品和销售团队满世界飞；而现在，一种相反的场景正在频繁出现——海外客户主动来中国“出差”。数据正在印证这一趋势：5月落幕的杭州第二届国际人形机器人展，累计达成合作签约56项、合作意向237项，总金额超213亿元人民币。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608153842453753.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608153842453753.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["AGIX","PBOT","QTOC","AIPO","KOMP","ROBO","CHAT","BD","ARTY","VTHR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659152904","title":"別慌！機構資金都流向了這裏！","url":"https://stock-news.laohu8.com/highlight/detail?id=2659152904","media":"证券市场周刊","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659152904?lang=zh_tw&edition=fundamental","pubTime":"2026-08-13 20:23","pubTimestamp":1786623796,"startTime":"0","endTime":"0","summary":"今天（8月13日），A股早盘三大指数集体高开，CPO等板块全线走强，“易中天”强势上涨，封板个股比比皆是。然而，下午2点左右，画风突变，上午追高的资金，午后被悉数套牢，截至收盘，仅创新药一枝独秀。那么，科技冲高回落，医药逆势爆发，这究竟发生了什么？今天这篇文章，笔者将逐一拆解。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608133840675371.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608133840675371.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02846","03188","KURE","83188","BK1583","03130","07233","BK4007","CPI","LU0828237510.HKD","BD","BK1588","06978","02827","159982","OCS","LNGR","LU1303224171.USD","LU0588546209.SGD","BK1147","06160","LU0307460666.USD","LU0228659784.USD","LU2328871848.SGD","LU1969619763.USD","LU1770034418.SGD","LU1719994722.HKD","83130","BK1574","MEDX","399300","LU1251922891.USD","BK1161","BK1500","IBBQ","82846"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659138728","title":"三筆重磅BD同日落地，創新藥出海景氣走高！T+0恒生創新藥ETF華泰柏瑞（520500）近一年累計「吸金」超25億元","url":"https://stock-news.laohu8.com/highlight/detail?id=2659138728","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659138728?lang=zh_tw&edition=fundamental","pubTime":"2026-08-13 13:07","pubTimestamp":1786597620,"startTime":"0","endTime":"0","summary":"据悉，恒生创新药ETF华泰柏瑞紧密跟踪的恒生创新药指数通过QDII机制投资40家港股创新药龙头企业，主要聚焦于生物制药、化学制药及原料药等中上游创新药领域，集结了一批研发实力强劲、具备发展潜力的研发驱动型企业。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-08-13/doc-inincxku3342998.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LNGR","BK1161","MEDX","520500","06978","159992","IBBQ","BD","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659818956","title":"白宮新聞秘書辭職；交易所BD曬12萬U提成引熱議；但斌調倉曝光；A股股民轉戰X","url":"https://stock-news.laohu8.com/highlight/detail?id=2659818956","media":"BitPush","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659818956?lang=zh_tw&edition=fundamental","pubTime":"2026-08-13 07:36","pubTimestamp":1786577775,"startTime":"0","endTime":"0","summary":"亲爱的读者朋友们好~\n过去24小时，X上的KOL们在聊什么呢？\n注：以下内容整理自X平台，均为个人观点，不代表本平台立场，更不构成投资建议。\n白宫新闻秘书辞职\n\n\n\n\n某交易所BD晒12W U 提成，引发争议\n\n\n\n\n但斌Q2持仓动作！\n\n\n\nA 股股民，去X上编小作文了\n\n\n\n\nTwitter：https://twitter.com/BitpushNewsCN\n比推 TG 交流群：https://t.me/BitPushCommunity\n比推 TG 订阅： https://t.me/bitpush\n\n\nKOL","market":"us","thumbnail":"https://images.bitpush.news/2026/02/special_cn-20260213-177094771056415446.jpg:1770947697448-200x140.jpg","type":0,"news_type":0,"thumbnails":["https://images.bitpush.news/2026/02/special_cn-20260213-177094771056415446.jpg:1770947697448-200x140.jpg"],"rights":{"source":"bit_push_news","url":"https://www.bitpush.news//articles/7670356","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.bitpush.news//articles/7670356","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"bit_push_news","symbols":["BD","SOCL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659186026","title":"從「搶BD」到重現金流 創新藥產業投資邏輯生變","url":"https://stock-news.laohu8.com/highlight/detail?id=2659186026","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659186026?lang=zh_tw&edition=fundamental","pubTime":"2026-08-13 07:26","pubTimestamp":1786577165,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["06978","159399","BK1574","SPHQ","BK4585","MEDX","IBBQ","BK1161","LNGR","BD","BK4588","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659186206","title":"從「搶BD」到重現金流 創新藥產業投資邏輯生變","url":"https://stock-news.laohu8.com/highlight/detail?id=2659186206","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659186206?lang=zh_tw&edition=fundamental","pubTime":"2026-08-13 07:15","pubTimestamp":1786576513,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4585","IBBQ","LNGR","MEDX","BK4588","SPHQ","BD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658950539","title":"百濟神州與Revolution Medicines宣佈合作；甘李藥業宣佈減肥新藥海外BD | 醫藥早參","url":"https://stock-news.laohu8.com/highlight/detail?id=2658950539","media":"每日经济新闻","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658950539?lang=zh_tw&edition=fundamental","pubTime":"2026-08-11 07:01","pubTimestamp":1786402877,"startTime":"0","endTime":"0","summary":"丨2026年8月11日星期二丨NO.1百济神州与RevolutionMedicines宣布达成临床开发及区域商业化合作8月10日，百济神州宣布与全球专注癌症药物研发的生物科技公司RevolutionMedicines达成一项多方面合作协议，涵盖临床联合开发与区域商业化授权两大核心板块，旨在加速RAS驱动型癌症的创新疗法研发与市场落地。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608113837029212.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608113837029212.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4588","IE0009355771.USD","BK1588","LU1251922891.USD","BK1574","BBH","RVMD","KURE","LU1303224171.USD","BD","IE00BJT1NW94.SGD","LU0588546209.SGD","LU0228659784.USD","CANC","IE00B4R5TH58.HKD","LU0828237510.HKD","603087","PTH","LU0889565916.HKD","LU1719994722.HKD","LU1770034418.SGD","IE0009354923.USD","IDNA","LU2328871848.SGD","BK4139","09939","ONC","IE00BJJMRZ35.SGD","LU0109394709.USD","LU1969619763.USD","BK4526","688235","BK1500","IE00B2B36J28.USD","IE0002141913.USD","IE00BFTCPJ56.SGD","LU0320765992.SGD","BK1515","06160","BK0239","159938","LU0307460666.USD","BK1583","BK4585","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658986658","title":"從BD高光到虧損迴歸，百利天恒面臨什麼考題？","url":"https://stock-news.laohu8.com/highlight/detail?id=2658986658","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658986658?lang=zh_tw&edition=fundamental","pubTime":"2026-08-10 15:49","pubTimestamp":1786348144,"startTime":"0","endTime":"0","summary":"相对于坎坷的赴港闯关之路，在生物科技这条赛道上，百利天恒已有产品实现商业化。从项目成熟度看，百利天恒并非停留在“早期研发概念验证”阶段。盈利高峰来自授权兑现，亏损继续扩大百利天恒最容易抓住眼球的，是其利润表在近两年出现过明显波动。这组数据本身已经足够说明，百利天恒并不是一家已经进入稳定盈利通道的创新药企业。从这个角度看，百利天恒的长板与短板都很鲜明。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1786328428501757201","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["688506","91194","BD","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658792716","title":"BD交易破千億美元 中國創新藥距離「全球大單品」還有多遠？","url":"https://stock-news.laohu8.com/highlight/detail?id=2658792716","media":"华夏时报网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658792716?lang=zh_tw&edition=fundamental","pubTime":"2026-08-09 12:36","pubTimestamp":1786250165,"startTime":"0","endTime":"0","summary":"8月5日，上海。2026沙利文峰会生命科学新投资高峰论坛上，一组数据让在场者屏息：2026年上半年，中国创新药对外授权（License-out）交易潜在总额达1100亿美元，交易规模达到2025年全年的八成。全球Top10BD交易中，中国独占8席。八年前，当港交所18A章刚刚落地时，中国创新药企还在用“烧十年钱、做研发、等审批”的循环艰难求生。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608093835903315.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608093835903315.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BD","KURE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657680386","title":"BD 2026財年第三季度財報：營收增長但營業利潤下滑","url":"https://stock-news.laohu8.com/highlight/detail?id=2657680386","media":"TradingKey中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657680386?lang=zh_tw&edition=fundamental","pubTime":"2026-08-06 18:42","pubTimestamp":1786012961,"startTime":"0","endTime":"0","summary":"BD 2026财年第三季度营收49.83亿美元，同比增长5.4%；持续经营稀释EPS为1.64美元，增长4.5%。营业利润下降10.3%，调整后EPS指引下限上调。","market":"us","thumbnail":"https://resource.tradingkey.com/cdn/images/article/news/trader1.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cdn/images/article/news/trader1.jpg"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/zh-hans/news/earnings/262082575-tradingkey","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BD","SQMX","PSET"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656374770","title":"「新新三樣」之中國創新藥：千億級BD背後的體系突圍","url":"https://stock-news.laohu8.com/highlight/detail?id=2656374770","media":"华夏时报网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656374770?lang=zh_tw&edition=fundamental","pubTime":"2026-08-03 21:33","pubTimestamp":1785763991,"startTime":"0","endTime":"0","summary":"今年以来，中国制造出海出现了越来越多新面孔。前两年，电动载人汽车、锂电池、太阳能电池被称为出口“新三样”，而今年上半年，机器人、人工智能、创新药成为未来产业方向的“新新三样”。数据显示，中国创新药企2026年上半年的海外授权（BD）交易总额，逼近2025年全年1357亿美元的七成，较2024年更是近乎翻倍。然而，比这一惊人数字更值得关注的，是交易结构的深层质变。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608033830056118.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608033830056118.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BD","KURE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656322031","title":"【券商聚焦】華泰證券維持先聲藥業（02096）買入評級 指新品放量及BD常態化","url":"https://stock-news.laohu8.com/highlight/detail?id=2656322031","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656322031?lang=zh_tw&edition=fundamental","pubTime":"2026-08-03 17:18","pubTimestamp":1785748719,"startTime":"0","endTime":"0","summary":"在行业波动背景下，公司超预期的业绩表现展现了新品种的强烈市场需求及高管变动后的效率提升，同时BD的常态化有望带来持续新增量。预计全年内生业务维持中报预告趋势，利润端受益于BD将继续跨越式提升。此外，在SIM0709年初实现BD及SIM0500后续潜在里程碑等带动下，预计公司合作收入将步入常态化，带来持续的收入增量。TCE平台SIM0500的I期数据有望年内读出，TOPOi毒素ADC平台已通过SIM0613和SIM0505的BD出海得到全面验证。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1987337","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KCE","02096","BD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655335512","title":"第十二批國採現場：多家金融機構到場介紹「集採貸」「BD貸」等服務產品","url":"https://stock-news.laohu8.com/highlight/detail?id=2655335512","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655335512?lang=zh_tw&edition=fundamental","pubTime":"2026-07-31 10:46","pubTimestamp":1785465967,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BD","FISI","BK4211"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655247857","title":"上半年BD交易破千億，創新藥長期趨勢向好？","url":"https://stock-news.laohu8.com/highlight/detail?id=2655247857","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655247857?lang=zh_tw&edition=fundamental","pubTime":"2026-07-29 16:08","pubTimestamp":1785312480,"startTime":"0","endTime":"0","summary":"2026年以来，创新药指数较年初有一定调整，有机构认为，这主要受阶段性行业偏好变化等市场因素影响。2026年上半年全球医药交易前十大事件中，中国药企占据八席。据东方证券统计，2026年BD交易的平均首付款和平均交易金额分别达0.6亿美元和10.6亿美元，同比分别增长38%和22%。机构表示，此举有望提升国产创新药临床可及性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/jjh/2026-07-29/doc-iniknezp2657599.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["06978","BD","BK1161","BK1574","LNGR","IBBQ","MEDX","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653758618","title":"專訪百奧賽圖沈月雷：「揭秘」一筆四個月就達成的BD合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2653758618","media":"新浪财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653758618?lang=zh_tw&edition=fundamental","pubTime":"2026-07-22 16:15","pubTimestamp":1784708100,"startTime":"0","endTime":"0","summary":"　　从双方正式启动合作到完成协议签署，历时仅仅约四个月，回顾百奥赛图与纳斯达克上市公司Whitehawk Therapeutics的BD合作，整个项目推进速度远快于行业同类项目。百奥赛图董事长兼CEO沈月雷博士在接受动脉网访谈时如此评价。　　据了解，近日百奥赛图与Whitehawk Therapeutics， Inc．宣布双方已签署一项全球战略合作协议，涵盖多个双特异性抗体偶联药物研发项目，双方将共同推进多元化的新一代治疗产品管线。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/enterprise/cn/2026-07-22/doc-iniisiee8049992.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0216","688796","BD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653237792","title":"遼BD*****、遼BF*****、遼BT****、遼B*****，你被曝光了！大連為啥這麼做？","url":"https://stock-news.laohu8.com/highlight/detail?id=2653237792","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653237792?lang=zh_tw&edition=fundamental","pubTime":"2026-07-21 11:44","pubTimestamp":1784605440,"startTime":"0","endTime":"0","summary":"辽望观天下）最近，大连对出租车行业刚柔并济的管理，收获“大赞”。大连同步推出“的哥的姐说大连，城市故事传四方”活动，鼓励司机为外来乘客讲城市历史、风土人情。不回避服务乱象、主动滋养行业荣誉感，内外兼修，才能让城市口碑行稳致远。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/wm/2026-07-21/doc-iniiptrh9371401.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652968292","title":"超百億資金悄悄買入這個賽道！","url":"https://stock-news.laohu8.com/highlight/detail?id=2652968292","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652968292?lang=zh_tw&edition=fundamental","pubTime":"2026-07-20 18:20","pubTimestamp":1784542804,"startTime":"0","endTime":"0","summary":"发生了什么？","market":"fut","thumbnail":"https://img3.gelonghui.com/3b82f-545adabe-fec1-4670-a0b5-27a6cec8d77f.jpg?guru_height=2611&guru_width=4570&guru_size=1374188","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/3b82f-545adabe-fec1-4670-a0b5-27a6cec8d77f.jpg?guru_height=2611&guru_width=4570&guru_size=1374188"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/5653295","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["159938","BD","BK1574","BK4585","IBBQ","BK4588","BK0216","FDN","BK1576","560260","513120","603127","BK4550","BK1141","515120","MEDX","06978","06127","BK1161"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":32,"code":"91000000","status":"200"}]}}